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Sary Inhibin is a polypeptide hormone produced by the granulosa cells of the ovary, and is present in
body as dimers of vanous sies each compnsng an a- and a-subunit. Free forms of the a-subunit also
circulate, and the presently available radioimmunoassay (Monash asy) cannot distinguish these from
biologicaly active dimeric inhibin. Recently we described a new two-site enzyme immunoassay able for the
first time to measure the kvels of dimeric inhibin throughout the human menstrual cycle. The sensitivity limit
of this assay is 2 pg ml-' in human serum with cross-reactivity against activin of 0.05%. The normal range of
inhibin in post-menopausal women is <5 pg mll, in pre-menopausal women 2-80 pg ml (2-10 pg ml iin
the follicular phase, 40-80 pg ml-' in the luteal phase). This assay was used to determine inhibin levels in sera
from 15 (five pre-menopausal and ten post-menopausal) patients with granulosa cell tumours of the ovary. It
was raised in a pre-menopausal patient preoperatively (261 pg ml -), in six post-menopausal patients (32, 43,
54, 66, 24 and 58 pg ml') and one pre-menopausal patient with recurrent tumour, (237 pg mni'), all
confirmed cinially. Inhibin was normal in six patients in remission. Oestradiol levels were normal in all
patients. Serial levels ofinhibin predicted recurrence before overt clinical relapse in two patients. In 29 patients
with malignant epithelial ovarian tumours inhibin levels were modestly elevated in nine and normal in the rest
Three patients with endometroid histology, two with undifferentiated tumours, three with muinous adenocar-
cinoma and one with clear cell carco had elvated inhibin kvels. Functional inhibin is sect by all
granulosa cell tumours of the ovary studied and can be used as a tumour marker to determine response to
therapy and predict recurrence and is supeior to oestadiol. A more detailed analysis of the klvels of inhibin,
and its subunits in epitheial ovarian cancer is needed to identify the moklular forms of the immunoreactive
material before optimised assays can be appled to this more common tumour.
Kcywor inhibin; ovarian cancer
The incidence of ovarian cancer in England and Wales is
approximately 5000 new cases per annum. It is the fourth
commonest cancer in women and the leading cause of death
from gynaecological cancer. In a recent meta-analysis of all
randomised clinical trials in ovarian cancer after surgery, the
median survival was 30% at 5 years (Advanced Ovanan
Cancer Triallst's Group, 1991). The poor survival is due to
patients presenting at an advanced stage of the disease, and
consequently screening for early detection has been inten-
sively investigated. There are still no reliable screening proce-
dures which detect ovarian cancer consistently. Ovarian
cancer itself comprises epithelial ovarian cancer (90%) and
sex cord-stromal tumours (10%). Biochemical markers for
epithelial ovarian cancer include CA-125, which is particular-
ly useful in serous adenocarcinomas, in which it is elevated
(80% ofcases) and has been found to be useful as a prognos-
tic indicator (Jacobs and Bast, 1989). In stromal tumours,
particularly granulosa cell-tumours, oestradiol and more
recently inhibin have been reported as useful markers reflect-
ing presence of disease (Lappohn et al., 1989). A recent
report demonstrated that inhibin is also elevated in post-
menopausal women with mucinous tumours of the ovary,
which normalise after surgery (Healy et al., 1993).
Inhibin is a polypeptide hormone produced by the granu-
losa cells of the ovary and which inhibits follicle-stimulating
hormone (FSH) secretion by the anterior pituitary gland.
Although its existence was first hypothesised in 1932 (Mc-
Cullagh, 1932) it was not until 1986 that the measurement of
serum inhibin levels became possible (Tsonis et al., 1986). A
radioimmunoassay (RIA) to measure inhibin levels through-
out the normal female menstrual cycle, commonly called the
Monash assay (McLachlan et al., 1987), was reported in
1987. Inhibin is a glycoprotein made of two subunits; an
a-subunit and a a-subunit, giving rise to two generic forms
(A and B) of apparently identical biological activity. In addi-
tion, in both serum and follicular fluid there exist other
related polypeptides: activin, follistatin and free £-subunits.
Current radioimmunoassays are unable to distinguish
between dimeric (biologically active) forms of inhibin and
free (biologically inactive) a-subunits (Schneyer et al., 1990).
There is a widely-recognised need for a convenient and sen-
sitive immunoassay which can detect the dimeric form of
inhibin and distinguish it from free inactive forms of the
a-subunit, which may occur in greater amounts in follicular
fluid and serum.
The recent development of a new sensitive two-site
immunoassay using monoclonal antibodies to the a-subunit
and the a-A-subunit of inhibin, developed by synthetic pep-
tide immunisations, has been instrumental in evaluating
levels of dimeric inhibin in serum (Groome and O'Brien,
1993; Groome et al., 1994). The assay can detect as litle as
2 pgml-1 of dimeric inhibin in human serum and plasma
(Groome et al., 1994) and has now been used in measuring
levels in sera of patients with both granulosa cell tumours of
the ovary and epithelial ovarian cancer. This assay specific-
ally measures dimeric biologically active inhibin with high
sensitivity in both pre- and post-menopausal women. The
results confirm the earlier report that inhibin is a valuable
tumour marker in granulosa cell tumours, and at least some
of the inhibin secreted is the biologically active dimeric form.
The decline of inhibin levels to normal range or elevation
above it correlates with the clinical status in each patient.
Thus, inhibin levels are valuable in predicting recurrence and
response to treatment in granulosa cell tumours of the ovary
and are complementary to oestradiol levels. By contrast, in a
limited study of sera from patients with epithelial ovarian
cancer, elevated dimeric inhibin levels were detected in a
smaLler proportion of patients with active disease. There was
no direct correlation with a particular histological subtype.
The significance of secretion of functional inhibin by
epithelial tumours of the ovary is not clear.
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Reuts Materias and methods
Patients
The majonrty of patients were treated either at the ICRF
Clinical Oncology Unit, Churchill Hospital, Oxford, or at the
ICRF Medical Oncology Unit, St. Bartholomew's Hospital,
London, UK. A proportion of serum samples were from
patients treated at other centres in the UK. The sera from
patients were stored in liquiid nitrogen.
Assays
Inhibin The technique for the two-site enzyme linked
immunosorbent assay has been described previously (Figure
1) (Groome and O'Brien, 1993; Groome et al., 1994). Briefly,
the assay is based on the use of an immobilised monoclonal
antibody (E4) to the n-A-subunit as capture antibody. The
Fab fraction of a mouse monoclonal antibody to the N-
terminal portion of the 20 kDa ca-subunit (RI) conjugated to
alkaline phospatase is used for detection. The monoclonal
antibody E4 is coupled covalently to a microtitre plate
(Avidplate-HZ) through the carbohydrate residues on the Fc
of the anitbody. This antibody captures dimeric inhibin from
the sample or standards via the a-A-subunit ignoring free
a-subunits. After a wash, the Fab/alkaline phosphatase con-
jugate is added and binds to the previously captured dimeric
inhibin. Following a final wash, the alkaline phosphatase is
detected by a sensitive amplified enzyme assay (AMPAK,
Dako Diagnostics). The use of hydrazide-treated plates
ensures full recovery of inhibin from serum and plasma.
Samples and standards were pretreated with 1% hydrogen
peroxide for 30 min before the assay, to enhance detection of
inhibin by E4 (Groome et al., 1994). Recombinant inhibin A
was used as the standard. The sensitivity limit of this assay is
2 pg ml-' in human serum with cross-reactivity against
activin of 0.05%.
Other hormones Follicle-stimulating hormone (FSH) and
luteinising hormone levels were measured by radioimmuno-
assay using a standard kit (Ferguson et al., 1982; Beastall
et al., 1987). The normal laboratory range for FSH is
0.5-8.0 IU I` in pre-menopausal and above 30 IU 1-1 in
post-menopausal women. Oestradiol levels were measured
using a commercially available kit by radioimmunoassay
(Gamma B-Direct Oestradiol Kit, Immunodiagnostic Systems).
The normal laboratory range is 75-300 pmol 1` in pre-
menopausal and less than 40 pmol 1-' in post-menopausal
women.
CA-125 CA-125 levels in sera were measured using a com-
mercially available kit by enzyme immunoassay (Cobas Core,
CA-125 II EIA). The normal value is less than
36 U ml-'.
Substrate Colour
Rl Fab
fragment
IH COO a-subunitI20K
NH2 | COOH >-A-subunit I12K
E4 Monoclonal
Antibody
Fugwe I Schematic diagram illustrating the principle of the
enzyme-linked immunosorbent assay.
Normal menstrual c)cle
After validation the assay was used to evaluate the levels in
sera from normal pre-menopausal and post-menopausal
women (Groome et al., 1994). In post-menopausal women,
dimeric inhibin was usually undetectable and never higher
than 5 pg ml-'. The levels of inhibin and the correlation with
FSH through a normal menstrual cycle of a premenopausal
woman are shown in Figure 2. The inhibin level is low in the
early follicular phase [3.4 pgml-', confidence interval (CI)
2.2-5.0 pg ml-'], increasing in the mid-follicular phase
(7.2 pgml-' CI. 5.9-8.8pgml-') and to a maximum in the
mid-luteal phase (65.6 pg ml-' CI 53.1-81.1 pgml-' ). The
concentration during the menstrual cycle varied 20-fold with
this assay. Similar results were obtained by daily estimation
of inhibin levels in normal women (Groome et al., 1994).
Granulosa cell twnours
Sera at different time points from five premenopausal and ten
post-menopausal patients with granulosa cell tumours were
assessed for inhibin concentrations. The levels of inhibin in
one premenopausal patient (Table 1, patient 1; Figure 3)
were high preoperatively and fell within the normal range
following surgery. It was also elevated in a patient at relapse
(Table I, patient 4) and associated with a low FSH level. In
two patients the levels were normal, while in another who
was in clinical and radiological remission the levels were
elevated above normal range. This patient was on oestrogen
replacement therapy.
In post-menopausal patients, the levels of inhibin were
elevated in six with active disease. The levels of FSH were
low when measured in the same serum sample. In four
patients whose disease was in remission inhibin was in the
normal range (Table II). The serial levels of inhibin in two
post-menopausal patients correlating with clinical status is
illustrated in Figures 4 and 5. In both patients inhibin levels
progressively increased before overt clinical relapse. Oes-
tradiol levels were in the normal range in all patients except
one (Table II, patient 7) with evidence of active disease.
Epithelial ovarian cancer
Inhibin levels were measured in 29 patients with malignant
epithelial ovarian tumours of varying histology (Table III).
The level was normal in all patients with serous adenocar-
cinoma preoperatively or at relapse. It was elevated above
the normal post-menopausal range (<5 pgml-' ) in eight
patients preoperatively and in one patient at relapse. The
FSH levels, however, did not always correlate with inhibin
levels. CA-125 levels were more accurately reflective of active
disease than inhibin. Serial levels from one patient with
endometrioid adenocarcinoma are shown in Figure 6.
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Flgwe 2 Serial inhibin (0) and FSH (*) levels in a normal
woman throughout a menstrual cycle. Inhibin and FSH were
measured from day 1 of menstruation.
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Table I Inhibin/FSH levels in sera of premenopausal women with granulosa cell tumours of the ovary
Age at Clinical data Inhibin/FSH (pgmln' IUl-') Oestradiol (pmol1-')
Patient diagnosis Stage Surgery Pre-op Remissio Relapse Remison Relapse
1 34 I Oophorectomy 261 10.8 <45
2 35 I Oophorectomy - <2.0 - 171
3 34 I Cystectomy - 5.04/1.0 - ND
4 33 HI TAH and BSO - - 237/1.3 <40
5 37 Ic Oophorectomya - 33/>40 - 218
'Patient on oestrogen replacement therapy following total abdominal hysterectomy (TAH) and oophorectomy at a later date. ND,
not done; BSO, bilateral salpingo-oophorectomy.
Tab e k Inhibin/FSH levels in sera of post-menopausal women with granulosa cell tumours of the ovary
Age at Clinial data Inhibin/FSH (pgml ' IUl1') Oestradiol (pmolI')
Patient diagnosis Stage Swrgery Pre-op Remission Relapse Remission Relapse
1 57 Ia TAH and BSO - 2 54/1.4 120 130
2 47 I TAH and BSO - - 43.3/5.5 <40
3 45 I TAH and BSO - - 32/1.5 <70
4 69 I TAH and BSO - 2 - <70
5 67 I TAH and BSO - 2 47.4
6 71 I TAH and BSO - 2/>40 - 40
7 65 I TAH and BSO - - 66 700
8 59 I TAH and BSO - <2 - ND
9 59 I TAH and BSO - - 24.3/2.3 o.or7
10 55 I TAH and BSO - 58.04 376
YOestradiol levels in nmol -' within normal limits. ND, not done.
0.f
Q
-c
._
._
Surgery
C
-c
.C
5 Months
10
Fugwe 3 Serial inhibin levels in a premenopausal patient with
granulosa cell tumour before and after surgery (Table 1, patient
1).
Clinical relapse
i n Death
Partial remission
CTH
Months
Fugwe 4 Serial inhibin levels in a post-menopausal patient with
granulosa cell tumour during course of her disease over 4 years.
CT, chemotherapy.
40
The assays currently in use for measuring inhibin in serum
have two limitations - sensitivity and cross-reactivity. The
Monash assay does not distinguish between dimeric inhibin
and the inactive a-subunits because of cross-reactivity
(Schneyer et al., 1990). The lowest detectable level of the
Monash assay is 60-70mUml', but acceptable precision
(intra-assay coefficient of variation of <10%) is achieved
only above 211 mU ml-1 in the normal follicular phase. Since
the normal range in the follicular phase is 100-1026mU
ml-', it appears that there may be difficulty in quantification
at the lower level of this range. This is particularly important
if the assay is to be used in monitoring recurrent ovarian
disease (Burger, 1993). A two-site immunoassay reported
recently could detect dimeric inhibin A only at levels above
1000pgml-1 (Baly et al., 1993). Further, the assay did not
detect inhibin in all samples, even from women undergoing
gonadotrophin therapy. By contrast, the assay used in this
report reproducibly detects 2 pgml' dimeric inhibin in
serum and has a cross-reactivity with activin of only 0.05%
(Groome and O'Brien, 1993; Groome et al., 1994). It is
non-isotopic, straightforward and measures only dimeric
inhibin, avoiding any cross-reaction with free a-subunits
secreted by the adrenal gland. However, at present any cross-
reactivity with larger forms of dimeric inhibin is un-
known.
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FIgwe 5 Serial inhibin levels in a post-menopausal patient with
granulosa ce}l tumour before detection of relapse and rapid fall
after surgery with increasing levels while in radiological remis-
sion.
The low inhibin levels in most post-menopausal women
confirms the physiological events following menopause. The
dimeric inhibin levels in normal menstrual cycles are similar
to those estimated with previous assays with two differences.
Fistly, inhibin concentration in the early follicular phase is
---I
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Table m Inhibin/FSH and CA-125 levels in sera of women with epithelial ovarian cancer
Clinical data Inhibin/FSH pgml-, IUl' CA125 IUml-'
Age at
Patient diagnosis Stage Surgery Pre-op Remission Relapse Pre-op Remission Relapse Histology
1 29 IV BSO 2 450 59 1150 Serous
2 54 III TAH and BSO 9/39.8 110 17 21 Endometrioid
3 62 III TAH and BSO 2 14 39 Serous
4 26 Ilb BSO <2 <2 47 18 Serous
5 58 III TAH and BSO <2 <2 1915 Undifferentiated
6 45 IIc TAH and BSO <2 <2/>40 500 8 311 Serous
7 51 III TAH and BSO <2/>40 536 Serous
8 40 II TAH and BSO <2/>40 81 16 1312 Serous
9 59 III Ascites drainage only <2 3104 750 Undifferentiated
10 47 III Biopsy only <2 58880 1430 11 182 Serous
11 55 II TAH and BSO <2/>40 36 558 Serous
12 61 III TAH and BSO <2/>40 1850 47 1536 Endometrioid
13 58 III TAH and BSO 25/>40 5/>40 343 17 Undifferentiated
14 54 III TAH and BSO 5.7/>40 106 Undifferentiated
15 61 III R ovary and omental biopsy <2/26.5 <2 736 4 Serous
16 57 III BSO <2/>40 210 71 688 Serous
17 49 III TAH and BSO 14/6.2 984 77 704 Clear cell
18 75 I TAH and BSO 8/37.5 52 Endometrioid
19 68 III TAH and BSO <2 <2 <2 500 10 500 Serous
20 63 IIc TAH and ISO <2 <2 23 10 - Undifferentiated
21 44 III TAH and BSO <2 <2 <2 173 292 Undifferentiated
22 63 III Biopsy only <2 10 500 Serous
23 49 III R. oophorectomy <2 <2 17 450 Serous
24 57 IIc L. oophorectomy <2 <2 22 500 Serous
25 70 III TAH and BSO 64.8/24.5 3.3/>40 500 13 Endometrioid
26 48 III TAH and BSO 11.5 <2 1440 34 Mucinous
27 27 Ia Cystectomy 44.5 7.67 47 29 Mucinous
28 73 III TAH and BSO 27.5 1.97 221 21 Mucinous
29 46 II TAH and BSO <2 75 Serous
TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy.
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Fugwe 6 Serial inhibin/FSH levels in a post-menopausal patient
with epithelial ovanran cancer before and after surgery. CT refers
to chemotherapy.
low in contrast to that observed with the Monash assay. This
is probably due to cross-reactivity of the Monash assay with
free a-subunits. Secondly, the magnitude of variations in
levels of inhibin through the cycle is considerably greater.
There is a 20-fold rise in this assay compared with only a
4-fold increase observed with the Monash assay (McLachlan
et al., 1987; Groome et al., 1994).
Granulosa cells tumours account for 2% of all ovarian
tumours. Although not considered aggressive tumours, the
long-term survival is poor in patients with extraovarian
spread, which is often late. The 20 year actuarial survival rate
is 34% (Dempster et al., 1987). Classically granulosa cells
produce oestradiol, but at least 30% of granulosa cell
tumours are steroidogenically inactive and most extraovarian
recurrences do not produce this hormone. Granulosa cells
also produce other peptide hormones inhibin, follistatin and
activin. Inhibin, after an assay was established to measure
levels in sera, was reported to be a marker for patients with
granulosa cell tumours and was elevated in all patients with
active disease, even when oestradiol levels were normal (Lap-
pohn et al., 1989). Several groups have confirmed this obser-
, 1- vation on a few natients. although the nature of inhibin
being measured was uncertain owing to the limitations of the
Monash assay. It was inferred that functional inhibin was
secreted by these tumours as it was associated with low FSH
levels, particularly in post-menopausal patients. The present
report is the first to demonstrate that functional dimeric
inhibin is secreted by granulosa cell tumours. The elevated
inhibin levels detected at presentation or at relapse correlate
with low FSH levels at the same time. Serial measurement of
inhibin levels in patients from whom sera were available
demonstrated a rise before the development of clinically overt
disease and a fall with subsequent therapy. In post-
menopausal patients the low levels of inhibin normally
detected (<2 pg ml-'), make it easy to detect recurrence. In
premenopausal patients in whom an ovary is conserved,
inhibin levels will vary with the menstrual cycle. The normal
level in the early follicular phase, immediately after men-
struation is less than 5 pg ml-'. It is therefore important to
interpret inhibin levels in relation to the menstrual cycle.
Follow-up serum samples in premenopausal women are best
taken at or immediately after menstruation when the basal
inhibin levels are low. The patient (5, Table 1) in whom
inhibin levels were elevated while in radiological remission
was on oestrogen replacement therapy. Serial samples have
not shown a progressive increase in levels. The oestradiol
level in patients with active disease was normal in all but one.
This, in association with elevated inhibin and low FSH levels,
suggests that it may be inhibin that is providing the feedback
control of FSH. Indirect evidence in support of this is pro-
vided by the observation of elevated FSH levels in patients
with gonadal failure on oestrogen replacement therapy
(Cameron et al., 1989). Measurement of inhibin levels in such
patients would be valuable in further understanding of the
relative roles of inhibin and ovarian steroids in the control of
FSH secretion.
The results in malignant epithelial ovarian tumours were
quite different. Inhibin was detected above the normal range
in eight patients preoperatively and in one at relapse. The
levels were slightly elevated; one patient alone had a level
greater than 50pgml-', and this was associated with low
FSH levels (Figure 6). Three of the nine patients with eleva-
ted levels had endometrioid adenocarcinoma, while another
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three had mucinous adenocarcinoma. The observation that
inhibin levels are elevated in mucinous adenocarcinoma
(Healy et al., 1993) could not be confirmed confidently
because there were only three such patients in this study.
However, no patient with serous adenocarcinoma had
abnormal levels. This study confirms that dimeric inhibin is
being measured in epithelial ovarian cancer, while the earlier
report measured inhibin-like immunoreactivity (Healy et al.,
1993). A larger prospective study needs to be performed to
evaluate the role of inhibin as a tumour marker in epithelial
ovarian cancer and to identify the various molecular forms
circulating in the serum of such patients. There are two
possible explanations for secretion of functional inhibin by
epithelial tumours. Firstly, it may reflect a stromal response
to the tumour. Secondly, it may reflect the intrinsic ability of
the surface epithelium of the ovary to secrete inhibin, as the
embryological origin is shared with the rest of the genital
tissue.
The development of tumour markers has been useful in
prognostic and therapeutic decision-making. This is exempli-
fied by the use of m-fetoprotein and -chorionic gonado-
trophin in the management of testicular cancer. The same
markers are useful in the management of yolk sac tumours,
teratomas and dysgerminomas of the ovary. In patients with
granulosa cell tumours, recurrences are often late, requiring
long-term follow-up. This reliable enzyme-linked immunosor-
bent assay for dimeric inhibin should be more valuable than
oestradiol in monitoring for recurrence during follow-up.
Detailed evaluation of the specificity and sensitivity of
inhibin as a tumour marker in granulosa cell tumours is
ongoing and would confirm the above preliminary observa-
tions. Further study of the inhibin molecular forms secreted
by epithelial ovarian tumours is required before any con-
clusion can be drawn about its potential as tumour marker in
such tumours.
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